Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2019 | 2018 | 2017 | 2016 | 2015 | 2014
Number of items: 16.

2019

Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

2018

Fuerstenau, M., Fink, A-M, Herling, C., Maurer, C., Kutsch, N., de la Serna, J., Coscia, M., Eckert, R., Crespo, M., Bosch, F., Noesslinger, T., Ghia, P., Kater, A. P., Boettcher, S., Ritgen, M., Schilhabel, A., Stilgenbauer, S., Tausch, E., Fischer, K., Hallek, M. and Eichhorst, B. (2018). B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide. Oncol. Res. Treat., 41. S. 172 - 174. BASEL: KARGER. ISSN 2296-5262

2017

Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Tausch, E., Seiler, T., von Weikersthal, Fischer L., Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 40. S. 24 - 25. BASEL: KARGER. ISSN 2296-5262

Edelmann, J., Tausch, E., Landau, D. A., Robrecht, S., Bahlo, J., Fischer, K., Fink, A. M., Bloehdorn, J., Holzmann, K., Boettcher, S., Werner, L., Kneba, M., Gribben, J. G., Neuberg, D. S., Wu, C. J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2017). Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia, 31 (3). S. 734 - 740. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Knittel, G., Korovkina, D., Liedgens, P., Rehkaemper, T., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P. -H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T. and Reinhardt, H. C. (2017). Novel models of high-risk CLL reveal an actionable PARP1 dependence in ATM-defective CLL in vivo. Oncol. Res. Treat., 40. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262

Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D-A, Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E. S., Stilgenbauer, S., Wu, C. J., Kiezun, A., Getz, G. and Brown, J. R. (2017). Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia, 31 (10). S. 2244 - 2248. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D. -A., Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E., Stilgenbauer, S., Wu, C., Kiezun, A., Getz, G. and Brown, J. (2017). GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica, 102. S. 65 - 66. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2016

Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M, Klaproth, H., Tausch, E., Fischer, K., Wendtner, C-M, Kreuzer, K. -A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262

von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Klaproth, H., Tausch, E., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Oncol. Res. Treat., 39. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262

2015

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Pflug, N., Maurer, C., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A. -M., Eichhorst, B., Kreuzer, K. -A., Tausch, E., Stilgenbauer, S., Boettcher, S., Doehner, H., Kneba, M., Hallek, M., Wendtner, C. -M., Bergmann, M. and Fischer, K. (2015). Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Tausch, E., Landau, D., Taylor-Weiner, A., Stewart, C., Reiter, J., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Boettcher, S., Cibulskis, K., Mertens, D., Sougnez, C., Rosenberg, M., Hess, J., Carter, S., Edelmann, J., Kless, S., Fink, A., Fischer, K., Ritgen, M., Kneba, M., Gabriel, S., Lander, E., Nowak, M., Doehner, H., Hallek, M., Neuberg, D., Getz, G., Stilgenbauer, S. and Wu, C. (2015). WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS. Haematologica, 100. S. 335 - 337. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2014

Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M. and Sharman, J. P. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 521 - 522. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Stilgenbauer, S., Hallek, M. J., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Coiffier, B., O'Brien, S. M., Tausch, E., Sharman, J. P., Ruppert, S., Schuster, A. and Kroenig, H. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262

This list was generated on Fri Jul 19 13:43:20 2024 CEST.